Expression of CD10 and Cytokeratins in Ovarian and Renal Clear Cell Carcinoma

Abstract

A solid pattern of tumor cells with a clear cytoplasm is common to both ovarian clear cell carcinoma (OvCCC) and renal clear cell carcinoma (RCCC). This study examined the possible differential expression of CD10 and cytokeratins (CK7, CK20, 34betaE12, and CAM5.2) between these two types. An immunohistochemical technique using peroxidase-labeled amino acid polymers was used to test formalin-fixed and paraffin-embedded tissues. In OvCCC, 6 of 29 cases were positive for CD10, and all cases had expression of CK7, 34betaE12, and CAM5.2. In contrast, all 24 RCCC cases had CD10 and CAM5.2 immunoreactivity, but none had any staining for 34betaE12. CK7 was only expressed in nine cases. No CK20 positivity was observed in any sample from either tumor type. Localization of CD10 expression was different in OvCCC versus RCCC. Although positive staining for 34betaE12 strongly suggests OvCCC, sometimes only a few cells may be stained. Therefore, 34betaE12-negative biopsies also should be evaluated for CD10 and CK7 immunoreactivity to enable histologic and cytologic differential diagnosis.

Diagnostic value of cytokeratin 7, CD10 and mesothelin in distinguishing ovarian clear cell carcinoma from metastasis of renal clear cell carcinoma

“…In the study by Ohta et al. , 24/24 RCCs were immunopositive for CD10, but 9/24 were also positive for CK7 6 . In the present study, 10/17 RCCs were positive for CD10 antibody and 2/17 RCCs for CK7, but with only a few tumour cells stained.…”

“…showed in their series that 29/29 OvCCC were diffusely positive for CK7, but 6/29 were also positive for CD10. CD10 immunoreactivity was observed at the apical border in four cases and in the cytoplasm in two 6 . Vang et al.…”

“…Immunohistochemistry might therefore be useful in doubtful cases. Among previous evaluated markers, cytokeratin (CK) 7 and CD10 have been shown to be the most appropriate but are not totally specific 5–9 . Mesothelin is a cell surface glycoprotein frequently expressed in ovarian neoplasia, but not in renal cell carcinoma 8 .…”

“…Ovarian metastases from RCC are rare but do occur 2–4 . Previous studies have evaluated several immunomarkers for the differential diagnosis 5–7 . CK7 and CD10 have been the most studied, with variable results 5,6 .…”

Role of Immunohistochemistry in Diagnosing Renal Neoplasms: When Is It Really Useful?

“…For example, CD10 is helpful for the diagnosis of metastatic RCC, but it is expressed in many other primary or metastatic carcinomas. 26,29,[81][82][83][84] Although AMACR is expressed in almost all metastatic papillary RCCs, it is expressed by other carcinomas, most notably, prostate adenocarcinoma; PAX8 detects most metastatic RCCs but is seen in most mü llerian tumors and thyroid malignancies. 21 The available data suggest that the panel for evaluating potential metastatic RCC should include PAX2 or PAX8, and RCC marker or CD10, supplemented by other markers dictated by the affected organ and/or the type of nonrenal tumors that may coexist.…”